Search the Newsreel

Why Medipharm Labs Corp stock is skyrocketing today

Innate Pharma prices €30M share offering to fund lead cancer drug

Innate Pharma has priced a €30 million share offering to fund the clinical development of its lead cancer drug candidate, IPH4502, and its preclinical antibody-drug conjugate portfolio. The French biotech issued 17,647,059 new ordinary shares at €1.70 each, expecting net proceeds of €27.6 million. …

Innate Pharma (IPHA) plans August 14, 2026 conference call and webcast

Four Innate Pharma executives set to appear in Aug. 14 webcast

Innate Pharma Seeks to Raise EUR23 Million from Share Offering

Innate Pharma is looking to raise EUR23 million through a share offering. This announcement comes after several recent developments, including an upgrade to Outperform by Leerink Partners, and a strategic partnership with Swedish Orphan Biovitrum AB for their drug Lacutamab, which is advancing to …

Earnings call transcript: MediPharm Labs posts first profit since 2019 in Q2 2026

Q2 2026 Medipharm Labs Corp Earnings Call Transcript

Why Medipharm Labs Corp stock surged yesterday

BTIG Maintains Innate Pharma(IPHA.US) With Buy Rating, Raises Target Price to $9

BTIG has reiterated its Buy rating for Innate Pharma (IPHA.US) and increased its price target to $9. This positive adjustment reflects the firm's continued confidence in the pharmaceutical company's prospects. Investors will be watching to see how Innate Pharma's stock performs following this analyst …

BTIG Research Issues Positive Forecast for Innate Pharma (NASDAQ:IPHA) Stock Price

FY2026 EPS Estimates for Innate Pharma Reduced by Analyst

Innate Pharma (NASDAQ:IPHA) Stock Rating Upgraded by Leerink Partners

Leerink Partners has upgraded Innate Pharma (NASDAQ:IPHA) from "market perform" to "outperform" with a $4.00 price target, suggesting an 80% upside. This follows similar upgrades from Citigroup and a higher price target from HC Wainwright, contributing to a consensus "Moderate Buy" rating and an …

Innate Pharma stock price target raised to $7 by H.C. Wainwright on Sobi deal

H.C. Wainwright has increased its price target for Innate Pharma (NASDAQ:IPHA) to $7.00 from $5.00, maintaining a Buy rating, following Innate Pharma's strategic partnership with Swedish Orphan Biovitrum for lacutamab. The deal, valued up to $465 million plus royalties, is expected to extend Innate …

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Given Average Rating of "Moderate Buy" by Analysts

Innate Pharma S.A. (NASDAQ:IPHA) has received an average rating of "Moderate Buy" from six analysts, with a consensus 12-month price target of $5.67. Recent analyst actions include HC Wainwright raising its price target to $7 and Citigroup upgrading the stock to "outperform." The company's …

Innate Pharma S.A.'s (EPA:IPH) Shift From Loss To Profit

Innate Pharma S.A. (EPA:IPH) is expected to transition from a loss-making position to profitability by 2027, according to analyst forecasts. The biotechnology company, which develops immunotherapies for cancer, reported a €49m loss in 2025 but is projected to achieve a €7.9m profit in 2027, …

Lacutamab Moves Toward Planned Phase 3 Trial in Rare T-Cell Lymphoma

Innate Pharma and Sobi have formed a strategic partnership to advance lacutamab, an anti-KIR3DL2 antibody, towards a Phase 3 clinical trial for cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides. The collaboration aims for accelerated approval in Sézary syndrome, with Sobi gaining …

Sobi broadens portfolio through Innate Pharma partnership

Sobi and Innate Pharma have formed a strategic partnership for lacutamab, a drug candidate for cutaneous T-cell lymphoma (CTCL). Sobi will gain exclusive global commercialization rights if accelerated approval is granted and holds an option for full development responsibilities after positive Phase III results. …

Sobi pens $580M deal for Innate’s cancer drug before ph. 3 push

Sobi has acquired global commercialization rights to Innate Pharma’s cancer drug, lacutamab, for $75 million upfront, with potential milestones up to $580 million. The deal will fund the phase 3 Tellomak-3 study for cutaneous T-cell lymphoma (CTCL), particularly Sézary syndrome, aiming for an accelerated …

Sobi adds rare lymphoma drug with $580m Innate tie-up

Sobi has entered a partnership with Innate Pharma, paying $75 million upfront and up to $505 million in milestones, for the rare lymphoma drug lacutamab. This deal allows Innate to initiate a phase 3 trial for lacutamab in Sézary syndrome, a rare form of …

Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO

(RTTNews) - Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study of Lacutamab, an investigational anti-KIR3DL2 antibody in …

Innate Pharma (NASDAQ: IPHA) secures Sobi deal, $75M upfront and Phase 3 push

Innate Pharma Names Markus Jensen Chief Medical Officer; Phase 3 Planned

Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy

Innate Pharma and Sobi have formed a strategic alliance, with Sobi providing an initial $75 million payment and up to $40 million in short-term developmental milestones, to advance a Phase 3 clinical trial for lacutamab, a rare skin cancer therapy. This collaboration aims to …

Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma

(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key step toward filing for accelerated approval of lacutamab in …

Innate Pharma plans phase 3 trial, names new medical officer By Investing.com

Innate Pharma SA (Euronext Paris: IPH; NASDAQ: IPHA) announced plans for a Phase 3 study of lacutamab for cutaneous T-cell lymphoma, contingent on a partnership with Sobi. The company also appointed Markus Jensen as its new Chief Medical Officer, effective September 1, 2026. The …

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study …

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

Innate Pharma has entered into a strategic partnership with Sobi to license lacutamab for T-cell lymphoma, aiming to accelerate its development and potential approval. Sobi will receive exclusive global commercialization rights, while Innate will conduct the TELLOMAK-3 Phase 3 study to support accelerated approval …

BlackRock Surpasses 3% Voting Rights in Uniphar PLC (UPR) with 7.83 Million Shares Held

Innate Pharma (IDDA) Q4 2023 Earnings Report - Results, Call & Slides

Innate Pharma (IDDA) released its Q4 2023 earnings report, showing an actual EPS of -€0.11, beating the consensus of -€0.38. However, the company missed revenue expectations with €15.53M against an expected €15.74M, despite a significant 112.69% YoY revenue growth. The earnings call took place …

Innate Pharma SA Class A Revenue Breakdown – EURONEXT:IPH

Innate Pharma SA (IPH) generated €9.01 million in revenue last year, primarily from its Research and Development of Pharmaceutical Products segment. This marks a decrease from €20.12 million in the previous year. France was the main contributor to the company's revenue, accounting for the …

IPHA|Innate Pharma SA|Price:1.820|Chg%:+0.020

Innate Pharma SA is a biopharmaceutical company based in France, focused on developing drugs for cancer and inflammatory diseases. The company identifies, characterizes, and manages the pre-clinical and clinical development of drug candidates, particularly focusing on immuno-modulators and cytotoxic antibodies. They have strategic collaborations …

Uniphar plc Posts 11% Adjusted EPS Increase in H1 2026 Amid Delay of Irish Distribution Hub to February 2027